Bimekizumab long-term efficacy in patients with plaque psoriasis from BE BRIGHT: Improvements in mean absolute clinical outcome scores over 4 years
Main Article Content
Keywords
Psoriasis
Abstract
Introduction: Bimekizumab (BKZ) has demonstrated long-term efficacy in patients (pts) with moderate to severe plaque psoriasis.1 Measuring response using absolute outcome scores may be clinically beneficial, as they are not influenced by baseline (BL) disease severity and provide a direct measure of current disease severity.2
We report improvements in absolute scores for psoriasis clinical outcomes through 4 years of BKZ treatment.
Procedure: Data were pooled from BE VIVID/BE READY/BE SURE (NCT03370133/NCT03410992/NCT03412747) and their open-label extension (OLE) BE BRIGHT (NCT03598790). Included pts received BKZ 320 mg every 4 weeks (wks; Q4W) to Wk16, then Q4W or Q8W into OLE.
Mean absolute Psoriasis Area and Severity Index (PASI), Investigator’s Global Assessment (IGA), body surface area (BSA) affected by psoriasis, and Dermatology Life Quality Index (DLQI) scores are reported to OLE Wk144 (Year4), using multiple imputation. Data were reported in all pts (BKZ Total), and in pts who received BKZ Q4W to Wk16 then Q8W (Q4W/Q8W).
Results: Among 771 BKZ Total pts, mean BL scores were: PASI 21.1; IGA 3.3; BSA 27.0; DLQI 10.5 (Q4W/Q8W: PASI 20.4; IGA 3.3; BSA 24.5; DLQI 10.8). Mean Wk16/Year4 scores were: PASI 0.6/0.7; IGA 0.4/0.5; BSA 1.4/1.2; DLQI 1.3/0.9. Scores in the 197 Q4W/Q8W pts at Wk16/Year4 were similar (PASI 0.3/0.6; IGA: 0.3/0.3; BSA: 0.7/1.2; DLQI: 1.3/0.7).
Conclusion: Improvements in mean absolute PASI, IGA, BSA, and DLQI were high by Wk16 and sustained through 4 years with BKZ.
References
2. Gordon KB et al. Lancet 2021;397:475–86 (NCT03410992)
3. Warren RB et al. N Engl J Med 2021;385:130–41 (NCT03412747)
4. Reich K et al. Lancet 2021;397:487–98 (NCT03370133)
5. Strober B et al. Br J Dermatol 2023;188:749–59 (NCT03598790)
6. Gerdes S et al. J Dermatol Treat 2020;31:470–5
7. Bimzelx® Summary of Product Characteristics. 2023.
Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx [Accessed March 2025]
8. Bimzelx® US Prescribing Information. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761151s000lbl.pdf [Accessed June 2025]
9. Mahil SK et al. Br J Dermatol 2020;182:1158–66
10. Armstrong AW et al. J Am Acad Dermatol 2017;76:290–8
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.